Yoshida K, Tosaka A, Takeuchi S, Kobayashi N
Department of Urology, Saitama Medical Center of Saitama Medical School, Japan.
Cancer. 1994 Apr 1;73(7):1913-8. doi: 10.1002/1097-0142(19940401)73:7<1913::aid-cncr2820730723>3.0.co;2-5.
The expression of epidermal growth factor receptor (EGFR) mRNA has been demonstrated in human renal cell carcinomas (RCC), but few reports quantitate EGFR in RCC and correlate EGFR content with clinicopathologic findings.
Using 125I-EGF as a ligand, the maximum binding of EGF in membrane preparations from RCC (EGFR content) was studied by Scatchard analysis.
A single class of binding sites for EGF was observed in 74% of RCC and 50% of normal renal tissues. The EGFR content was increased significantly in RCC compared with normal tissues. In all cases in which EGFR was undetectable, there was no evidence of distant metastasis, venous invasion, or regional lymph node involvement, and these patients had a better clinical outcome than patients with detectable EGFR. The EGFR content was significantly lower in nuclear Grade 1 tumors than in tumors of higher nuclear grades. No significant difference between EGFR content and other clinicopathologic findings was detected.
The determination of EGFR content in RCC may become an important prognostic factor for the biologic behavior of RCC.
表皮生长因子受体（EGFR）mRNA已在人类肾细胞癌（RCC）中得到证实，但很少有报告对RCC中的EGFR进行定量，并将EGFR含量与临床病理结果相关联。
以125I-EGF作为配体，通过Scatchard分析研究RCC膜制剂中EGF的最大结合（EGFR含量）。
在74%的RCC和50%的正常肾组织中观察到一类EGF结合位点。与正常组织相比，RCC中的EGFR含量显著增加。在所有未检测到EGFR的病例中，没有远处转移、静脉侵犯或区域淋巴结受累的证据，并且这些患者的临床结果优于可检测到EGFR的患者。核分级为1级的肿瘤中EGFR含量明显低于核分级较高的肿瘤。未检测到EGFR含量与其他临床病理结果之间的显著差异。
RCC中EGFR含量的测定可能成为RCC生物学行为的重要预后因素。
